EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids
Open Access
- 31 March 2008
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 27 (31) , 4336-4343
- https://doi.org/10.1038/onc.2008.71
Abstract
Doublet mutations in cancer are not well studied. We find that allelic somatic doublet mutations are present at high frequency in the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) domain in lung cancers. When doublets from the literature are added, a total of 96 doublets are available for analysis. The frequency of doublets overall is 6%, which is sevenfold greater than that observed in normal tissue in mouse. All characterized doublets are allelic, and silent mutations occur rarely. About half of all doublets contain one or two of 12 distinct missense mutations at five amino acids: E709, G719, S768, T790 and L861. The mutations at these five amino acids are seldom reported as singlets. Moreover, when the common L858 target is included, more than one-third of EGFR doublets are one of five specific missense pairs: G719/E709, G719/S768, G719/L861, L858/E709 and L858/T790. Structure suggests function: The data imply that most EGFR doublets are NOT consistent with a ‘driver and passenger’ mutation mechanism. EGFR doublets are highly skewed relative to singlets, consistent with functional selection of two individually suboptimal mutations that, in combination, have enhanced oncogenic potential.Keywords
This publication has 29 references indexed in Scilit:
- Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signatureHuman Mutation, 2007
- Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance MutationCancer Research, 2007
- Patterns of somatic mutation in human cancer genomesNature, 2007
- Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to GefitinibCancer Research, 2007
- Amplification, mutation and loss of heterozygosity of the EGFR gene in metastatic lung cancerInternational Journal of Cancer, 2007
- Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFRNature Genetics, 2005
- Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutantsOncogene, 2005
- Spontaneous multiple mutations show both proximal spacing consistent with chronocoordinate events and alterations with p53-deficiencyMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaSeminars in Oncology, 2002